Navigation Links
BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
Date:9/8/2009

HERNDON, Va., Sept. 8 /PRNewswire/ -- BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

BHR will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), closed-head trauma TBI at 100-120 medical centers in the United States, Europe, Israel and additional countries.

Randomized patients will receive a five-day (120-hour) intravenous infusion of progesterone or placebo. Unlike intravenous progesterone infusions described in the medical literature, BHR-100 is a ready-to-use infusion designed to meet all U.S. Food and Drug Administration approval requirements.

BHR is collaborating with the American Brain Injury Consortium (ABIC) and the European Brain Injury Consortium (EBIC) to identify the trial sites and help design the clinical study. PRA International is the Contract Research Organization for the trial.

TBI is a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to permanent or temporary impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

Approximately 1.5 million Americans per year suffer a traumatic brain injury, resulting in 50,000 deaths, 235,000 hospitalizations and 80,000 cases of long-term disability. Incidence of TBI in all industrialized countries is comparable to that in the U.S., with estimates ranging from 150 to more th
'/>"/>

SOURCE BHR Pharma, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
4. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
5. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
6. Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
10. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
11. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
... DIEGO, May 7, 2012 Volcano Corporation (NASDAQ: ... therapy tools designed to enhance the diagnosis and treatment of ... be participating in the 11th Annual JMP Securities Research Conference ... Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific ...
... Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, ... (FDA) has lifted the clinical hold previously placed on ... patients with Pseudomonas lung infections. ... CF clinical trial population consisting of adult patients who ...
Cached Medicine Technology:Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections 2Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections 3
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec ... are thought to have been behind the attack on Anthem Inc. which resulted in ... day exploits, watering hole attacks and spear phishing campaigns. , For Joe ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... , Nurtur Receives ... Nov. 23 The Population Health Impact Institute (PHII), a ... of Directors has approved the Healthcare Transparency Accreditation Program, v ... life, health, and wellness company based in Farmington, CT is ...
... than most friends, relatives or even healthcare professionals realise, according ... issue of the UK-based Journal of Advanced Nursing . ... had undergone surgery in the last year, together with 105 ... years at the Vanderbilt Transplant Center in Tennessee, USA. They ...
... ... Compliance Requirements and Automate Billing, Claims, Enrollment and Eligibility, , ... (PRWEB) November 23, 2009 ... announced today the launch of new products within its healthcare integration suite, designed ...
... both increased risk eightfold , MONDAY, Nov. 23 (HealthDay ... who were exposed to lead have more than double ... other children, new research shows. , And with exposure ... ADHD soared. Children whose mothers smoked during pregnancy and ...
... , SANTA CLARA, Calif., Nov. 23 NewCardio, Inc., (OTC ... CEO, Dr. Branislav Vajdic, and CFO, Richard Brounstein, will present at ... 4:30 PM PST at the Luxe Sunset Hotel in Los Angeles. ... December 2nd and Thursday, December 3rd. Please contact Brett Aimee ...
... ... as Best New Technology Provider for its QlikView Business Intelligence Software , ... Radnor, PA ... company, today announced that it was recognized with the Healthcare IT Innovation™ Award ...
Cached Medicine News:Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 2Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 3Health News:BridgeGate Launches New Healthcare Integration and Interoperability Products 4Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 2Health News:Smoking During Pregnancy, Lead Exposure Raise ADHD Risk in Kids 3Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 2Health News:QlikTech Wins Healthcare IT Innovation™ Award 3Health News:QlikTech Wins Healthcare IT Innovation™ Award 4
... Left Ventricular Assist System (LVAS), manufactured by ... used as a destination therapy for patients ... heart failure, for which heart transplantation is ... is not intended as a bridge to ...
... The TandemHeart PTVA ( Percutaneous ... unique proprietary solution for the hemodynamic needs ... Cardiologists and Cardiac Surgeons. These specialists ... provide some coronary artery perfusion, but the ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
Medicine Products: